Published in Neuropharmacology on March 24, 2006
Molecular targets for antiepileptic drug development. Neurotherapeutics (2007) 1.78
Metabotropic glutamate receptor subtype 5 antagonism in learning and memory. Eur J Pharmacol (2010) 1.07
Effects of the mGluR2/3 agonist LY379268 and the mGluR5 antagonist MPEP on handling-induced convulsions during ethanol withdrawal in mice. Alcohol (2008) 0.81
Effects of subtype-selective group I mGluR antagonists on synchronous activity induced by 4-aminopyridine/CGP 55845 in adult guinea pig hippocampal slices. Neuropharmacology (2008) 0.80
Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx (2005) 2.44
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol (2005) 2.43
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology (2007) 2.39
Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein bassoon. Neuron (2003) 2.31
Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol (2007) 1.97
Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther (2002) 1.60
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry (2003) 1.50
Anticonvulsant effects of transcranial direct-current stimulation (tDCS) in the rat cortical ramp model of focal epilepsy. Epilepsia (2006) 1.41
Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology (2005) 1.34
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res (2007) 1.28
Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol (2012) 1.26
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol (2009) 1.19
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology (2006) 1.18
mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology (2006) 1.15
The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect. Neuropharmacology (2005) 1.15
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology (2005) 1.12
Neurogenesis in the adult rat piriform cortex. Neuroreport (2006) 1.12
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem (2007) 1.12
Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. Neuropharmacology (2007) 1.11
Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia (2002) 1.11
Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology (2011) 1.10
Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. Neuropharmacology (2009) 1.08
Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem (2005) 1.07
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis (2004) 1.07
Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology (2002) 1.06
Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther (2006) 1.05
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis (2010) 1.04
Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol (2006) 1.04
COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology (2009) 1.03
Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology (2006) 1.03
Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats. Psychopharmacology (Berl) (2006) 1.02
Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol (2005) 1.01
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull (2006) 1.00
Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol (2009) 1.00
Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav (2006) 1.00
Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia (2012) 0.99
Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. Eur J Pharmacol (2006) 0.99
Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur Neuropsychopharmacol (2005) 0.98
Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther (2009) 0.98
Modulation of neurogenesis by targeted hippocampal irradiation fails to affect kindling progression. Hippocampus (2010) 0.98
Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res (2013) 0.96
Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol (2009) 0.96
Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia (2006) 0.96
Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. J Biol Chem (2003) 0.95
Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther (2009) 0.95
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology (2009) 0.94
The role of excitotoxicity in neurodegeneration. Folia Neuropathol (2005) 0.93
Effects of mGlu1 receptor blockade on working memory, time estimation, and impulsivity in rats. Psychopharmacology (Berl) (2007) 0.93
Targeting epileptogenesis-associated induction of neurogenesis by enzymatic depolysialylation of NCAM counteracts spatial learning dysfunction but fails to impact epilepsy development. J Neurochem (2008) 0.93
Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacol Biochem Behav (2009) 0.92
The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning. Neuropharmacology (2009) 0.92
Behavioral characterization of GLT1 (+/-) mice as a model of mild glutamatergic hyperfunction. Neurotox Res (2008) 0.92
The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur J Neurosci (2004) 0.91
Analgesic effects of morphine and loperamide in the rat formalin test: interactions with NMDA receptor antagonists. Eur J Pharmacol (2005) 0.89
Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Epilepsia (2004) 0.88
The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. Neuropharmacology (2006) 0.88
Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res (2002) 0.88
Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res (2004) 0.88
Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder. Eur Neuropsychopharmacol (2008) 0.88
Effect of aging on neurogenesis in the canine brain. Aging Cell (2008) 0.88
Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats. Epilepsy Res (2003) 0.87
Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour. Neurosci Lett (2011) 0.87
Behavioural and cellular effects of exogenous amyloid-β peptides in rodents. Behav Brain Res (2011) 0.87
N-methyl-D-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice. Behav Pharmacol (2006) 0.86
Neuroprotective potential of group I metabotropic glutamate receptor antagonists in two ischemic models. Neurochem Int (2006) 0.86
Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia (2002) 0.86
N-methyl-D-aspartate receptors mediate endogenous opioid release in enteric neurons after abdominal surgery. Gastroenterology (2005) 0.85
In vivo imaging of dopamine receptors in a model of temporal lobe epilepsy. Epilepsia (2009) 0.85
A new automated method to assess the rat recognition memory: validation of the method. Behav Brain Res (2011) 0.85
Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res (2002) 0.84
Quantitative comparison of DNA detection by GFP-lac repressor tagging, fluorescence in situ hybridization and immunostaining. BMC Biotechnol (2007) 0.83
Effects of physiological and pharmacological stimuli on dopamine release in the rat globus pallidus. Neurochem Int (2005) 0.83
Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. J Neurochem (2007) 0.83
Impact of the PSA-NCAM system on pathophysiology in a chronic rodent model of temporal lobe epilepsy. Neurobiol Dis (2007) 0.83
Assessment of the effects of NS11394 and L-838417, α2/3 subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function. Behav Pharmacol (2012) 0.83
Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology (2004) 0.83
Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Behav Pharmacol (2011) 0.82
Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage (2009) 0.82
Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol (2002) 0.82
Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats. Behav Pharmacol (2008) 0.82
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats. ACS Chem Neurosci (2013) 0.81
Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice. Epilepsy Res (2010) 0.81
A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine. Psychopharmacology (Berl) (2008) 0.81
MAP-kinase-activated protein kinase 2 expression and activity is induced after neuronal depolarization. Eur J Neurosci (2008) 0.81